Search results
Order by most recent / most popular / relevance
Results: 1-10 of 196
Court grants motion to reopen trial and admit new evidence
- Borden Ladner Gervais LLP
- -
- Canada
- -
- April 27 2011
The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued
Leave to appeal to the Court of Appeal Re: motion to strike pleadings granted in respect of claims to unjust enrichment, denied in respect of claims under the Trade-Marks Act
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 6 2013
In this case, Apotex has sued Eli Lilly for damages pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations. Eli Lilly brought a
Ontario regulation prohibiting private label generic drugs declared ultra vires
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 16 2011
In 2010, regulations were made pursuant to each of the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA
Pharmacies not permitted to sell “private label” generic drugs
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 4 2012
The Government of Ontario appealed from two Orders of the Divisional Court declaring that sections of provincial regulations banning pharmacies from selling “private label” generic drugs are ultra vires and of no force and effect
Apotex Inc. v. Merck Frosst Canada & Co.
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 15 2010
This is an action decided under s 8 of the Patented Medicines (Notice of Compliance) Regulations between Apotex and Merck relating to norfloxacin
Pfizer Canada Inc. v. Novopharm, The Minister of Health, Northwestern University and the Board of Regents for the University of Oklahoma
- Borden Ladner Gervais LLP
- -
- Canada
- -
- July 5 2010
In a proceeding pursuant to the Patented Medicines (Notice of Compliance) Regulations, Novopharm brought a motion seeking a Protective Order that allowed the designation of Novopharm's Notice of Allegation (NOA) as confidential
Appeal of decision denying interlocutory injunction dismissed
- Borden Ladner Gervais LLP
- -
- Canada
- -
- July 4 2011
This was an appeal of a decision of the Federal Court, refusing an interlocutory motion
Appeal dismissed regarding motion granting leave to amend pleadings
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 12 2012
The Federal Court of Appeal (FCA) upheld a decision of the Motions Judge, which upheld the decision of a Prothonotary, granting leave to the respondents to amend their pleadings
Supreme Court of Canada considers patent sufficiency requirements
- Borden Ladner Gervais LLP
- -
- Canada
- -
- November 8 2012
The Supreme Court issued its decision today in the much-anticipated patent case involving VIAGRA sildenafil
Teva Canada Innovation v. Attorney General of Canada
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 8 2013
The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an
Current Search
- Author - Beverley Moore
- Workarea - Healthcare